Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.40
Bid: 110.40
Ask: 111.20
Change: 0.40 (0.36%)
Spread: 0.80 (0.725%)
Open: 110.00
High: 111.20
Low: 110.00
Prev. Close: 110.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks mixed; UK economic recovery slows

Wed, 22nd Dec 2021 09:12

(Alliance News) - Stock prices in London opened mixed on Wednesday amid concerns over the Omicron variant and government measures to contain it, while investors digested disappointing UK economic growth figures.

UK Prime Minister Boris Johnson on Tuesday gave the go-ahead for people's Christmas plans, although he warned tougher restrictions could be implemented post-December 25.

Johnson said "continuing uncertainty" about the severity of the Omicron variant and hospital admission rates means he does not believe there is enough evidence at the moment to justify stricter measures.

But the situation remains "finely balanced" and people should "exercise caution", Johnson added.

The FTSE 100 index was down 21.58 points, or 0.2%, at 7,275.83 early Wednesday. But the mid-cap FTSE 250 index was up 27.30 points, or 0.1%, at 22,847.60, and the AIM All-Share index was up marginally at 1,174.62.

The Cboe UK 100 index was down 0.2% at 722.37. The Cboe 250 was up 0.2% at 20,252.10, and the Cboe Small Companies was up 0.1% at 14,839.54.

In mainland Europe, the CAC 40 stock index in Paris was up 0.1%, while the DAX 40 in Frankfurt was 0.2% higher.

In Asia on Wednesday, the Nikkei 225 index in Tokyo closed up 0.2%. In China, the Shanghai Composite closed down 0.1%, and the Hang Seng index in Hong Kong ended up 0.6%. The S&P/ASX 200 in Sydney closed up 0.1%.

In the FTSE 100, Taylor Wimpey rose 0.3% after the UK Competition & Markets Authority ended its probe into the housebuilder over ground rents.

Taylor Wimpey said the CMA investigation into the historical sale of leasehold properties with doubling ground rent clauses by the company is closed, following the agreement of voluntary undertakings.

The housebuilder said the cost of the undertakings falls within the original provision Taylor Wimpey made in 2017. By entering into the undertakings there is no finding that Taylor Wimpey has infringed UK consumer law, it noted.

Conversely, Croda International was down 0.9%. The speciality chemicals company has agreed to sell the majority of its Performance Technologies and Industrial Chemicals businesses to Cargill for an enterprise value of EUR915 million on a cash-free, debt-free basis.

Croda said the disposal of the businesses follows the strategic review that it announced in May. The operations being sold represent 77% of PTIC's 2020 revenue and consist of five manufacturing facilities in the UK, China and the Netherlands.

Land Securities was down 0.1%. The property developer Land Securities bought a further stake in the Bluewater shopping mall outside London.

Landsec said it has completed the acquisition of an additional 25% share in Bluewater from Lendlease Retail Partnership for GBP172 million, representing a net initial yield of 8.15% and an equivalent yield of 8.25%.

In a separate deal, Landsec said it will sell 25% of this share - a 7.5% stake - to co-owner M&G for its pro rata share of the purchase price with the deal completing in April 2022. After this, Landsec's ownership of Bluewater will be 48.8%.

In the FTSE 250, Syncona was the best performer, up 8.5%, after the healthcare investor said its portfolio company Gyroscope Therapeutics will be sold to Swiss pharmaceutical company Novartis for up to USD1.5 billion.

Syncona has a 54% stake in Gyroscope following a USD42 million investment in March, after co-founding the business in 2016.

Novartis shares were down 0.3% in Zurich.

Pennon was down 0.3% after the CMA said the utility has until December 31 to give undertakings for its Bristol Water acquisition.

The regulator said the Pennon acquisition of Bristol Water may impede Ofwat's ability to make comparisons between water companies.

In response, Pennon said it intends to provide undertakings to CMA for Bristol Water by December 31.

The pound was quoted at USD1.3253 early Wednesday, up from USD1.3248 at the London equities close Tuesday, despite disappointing UK economic growth figures.

UK economic growth was revised lower in the third quarter on a quarterly basis but higher on an annual basis, figures from the Office for National Statistics showed.

On the quarter before, UK gross domestic product advanced by 1.1% in the three months to September, slower than a 5.4% rise in the three months to July, but missed consensus of an expansion of 1.3%, which would have matched the first estimate.

On a year before, the UK economy grew by 6.8% in the third quarter, slowing sharply from the 24% annual growth rate in the second quarter. The latest reading slightly beat the market forecast, cited by FXStreet, of 6.6% annual growth, which also would have matched the first estimate.

Analysts at Capital Economics said: "The downward revision to GDP in Q3 means the economy had a little less momentum going into the closing months of the year than we previously thought. And given early signs that the huge surge in Covid-19 infections has weighed on activity so far in December, GDP growth looks to have slowed in Q4.

"But these data are old news and predate the recent surge in virus infections caused by the Omicron variant. That already seems to have prompted a weakening of activity in December. And, although the economy has got better at coping with restrictions with each new wave, the possibility of tighter restrictions in January is further darkening the outlook for GDP."

The euro was priced at USD1.1270, firm from USD1.1267. Against the Japanese yen, the dollar was trading at JPY114.30, rising from JPY114.14.

Brent oil was quoted at USD74.14 a barrel on Wednesday morning, up from USD73.48 late Tuesday. Gold stood at USD1,786.23 an ounce, firm from USD1,785.40.

Wednesday's economic calendar has US GDP at 1330 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more
14 Nov 2023 11:29

IN BRIEF: Syncona notes investee company's quarterly loss

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles.

Read more
9 Nov 2023 15:44

UK earnings, trading statements calendar - next 7 days

Friday 10 November 
Allianz Technology Trust PLCQ3 Results
Wheaton Precious Metals CorpQ3 Results
Monday 13 November 
Bank of Cyprus Holdings PLCQ3 Results
British Land Co PLCHalf Year Results
Kainos Group PLCHalf Year Results
Team Internet Group PLCQ3 Results
Tuesday 14 November 
ActiveOps PLCHalf Year Results
Babcock International Group PLCHalf Year Results
Bank of Georgia Group PLCQ3 Results
Castings PLCHalf Year Results
ConvaTec Group PLCTrading Statement
DCC PLCHalf Year Results
Forterra PLCHalf Year Results
Gear4Music PLCHalf Year Results
Genel Energy PLCTrading Statement
HydrogenOne Capital Growth PLCQ3 Results
Hill & Smith PLCTrading Statement
Imperial Brands PLCFull Year Results
Informa PLCTrading Statement
Land Securities Group PLCHalf Year Results
Oxford Instruments PLCHalf Year Results
Picton Property Income LtdHalf Year Results
Renalytix PLCQ1 Results
Vesuvius PLCTrading Statement
Vodafone Group PLCHalf Year Results
Wise PLCHalf Year Results
Wednesday 15 November 
Diversified Energy Co PLCTrading Statement
Experian PLCHalf Year Results
Fuller, Smith & Turner PLCHalf Year Results
Genuit Group PLCTrading Statement
Intermediate Capital Group PLCHalf Year Results
Ninety One PLC and LtdHalf Year Results
Renold PLCHalf Year Results
SSE PLCHalf Year Results
Synthomer PLCTrading Statement
Tracsis PLCFull Year Results
Tullow Oil PLCTrading Statement
Warehouse REIT PLCHalf Year Results
Thursday 16 November 
Assura PLCHalf Year Results
Atalaya Mining PLCQ3 Results
Aviva PLCTrading Statement
Burberry Group PLCHalf Year Results
Close Brothers Group PLCTrading Statement
CMC Markets PLCHalf Year Results
Crest Nicholson Holdings PLCTrading Statement
Halma PLCHalf Year Results
Great Portland Estates PLCHalf Year Results
Kier Group PLCTrading Statement
International Distributions Services PLCHalf Year Results
Investec PLC and LtdHalf Year Results
Liontrust Asset Management PLCHalf Year Results
Manolete Partners PLCHalf Year Results
Melrose Industries PLCTrading Statement
Norcros PLCHalf Year Results
Premier Foods PLCHalf Year Results
Qinetiq Group PLCHalf Year Results
Spirax-Sarco Engineering PLCTrading Statement
Syncona LtdHalf Year Results
Tatton Asset Management PLCHalf Year Results
Tyman PLCTrading Statement
United Utlities Group PLCHalf Year Results
Young & Co's Brewery PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Nov 2023 11:51

TRADING UPDATES: Augmentum Fintech makes further investment in Tide

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:

Read more
18 Oct 2023 12:01

IN BRIEF: Syncona announces takeover offer for Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Says Syncona Investment Management Ltd has submitted a non-binding proposal to acquire the entire remaining share capital of Freeline Therapeutic Holdings PLC. Offers upfront cash consideration of USD5.00 per American depository share, representing a 20% premium over the USD4.16 volume weighted average price from October 4 to October 16. Syncona currently owns around 57.9% of shares in Stevenage, England-based Freeline, which it co-founded in 2015. Freeline aims to develop gene therapies to treat chronic diseases, most notably its potentially "transformative" FLT201 programme to treat Gaucher disease.

Read more
4 Oct 2023 14:28

Syncona says Freeline and SwanBio clinical trails make progress

(Alliance News) - Syncona Ltd on Wednesday said its portfolio company Freeline Therapeutics Holdings PLC has received positive initial safety, tolerability and enzyme activity data from its FLT201 trial for the treatment of Gaucher disease.

Read more
29 Sep 2023 09:51

IN BRIEF: Syncona launches GBP40 million share buyback programme

Syncona Ltd - London-based investor in healthcare companies - Launches share buyback programme worth up to GBP40.0 million, to be conducted by Numis Securities Ltd. Says core focus remains on allocating capital to portfolio companies' assets. However the buyback is necessary due to Syncona's shares currently trading at a discount to net asset value, which was 184.6 pence per share at June 30. Says buyback will not affect investments into clinical stage assets planned for the next 24 months. Company expects that capital deployment into portfolio and pipeline will total between GBP150 million and GBP200 million for the year ending March 31, in line with prior guidance. Chair Melanie Gee says Syncona "has a high level of confidence in our portfolio and its valuation".

Read more
11 Sep 2023 15:42

Syncona shares slump as Novartis ends eye treatment development

(Sharecast News) - Syncona shares fell as the UK healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, resulting in milestone payments write-off of £54.5m for Gyroscope Holdings in which Syncona once held a 54% stake.

Read more
11 Sep 2023 09:51

Syncona suffers negative valuation hit as Novartis discontinues GT005

(Alliance News) - Syncona Ltd on Monday said it has been informed by Swiss-American pharmaceutical company Novartis AG that the development of eye treatment, GT005, for geographic atrophy secondary to dry age-related macular degeneration will be discontinued.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
15 Aug 2023 13:56

IN BRIEF: Syncona notes clinical progress of portfolio firm Freeline

Syncona Ltd - London-based healthcare investor - Notes second quarter results announcement from its Nasdaq-listed portfolio company Freeline Therapeutics Holdings PLC. Says the key highlights include Freeline completing the dosing in the first dose cohort of the phase 1/2 trial of FLT201 in Gaucher disease, following dosing of the second patient. Says initial clinical data from the FLT201 trial is expected in the second half of 2023. Also says Freeline has a cash position of USD38.8 million at June 30 compared to USD55.4 million on March 31, which Freeline expects will enable the company to fund its planned operations into the second quarter of 2024. Freeline says net income in the three months that ended June 30 narrowed to USD14.8 million from USD51.1 million a year earlier.

Read more
10 Aug 2023 09:33

IN BRIEF: Syncona says net asset value slips 1% in first quarter

Syncona Ltd - London-based healthcare investor - Net asset value at June 30 is 184.6 pence per share, down 1.0% from 186.5p on March 31. NAV total return also was negative 1.0% for the recent three months, Syncona's financial first quarter. Notes performance was hurt by "negative foreign exchange movements" across its life science portfolio. This is valued at GBP628.7 million on June 30, up 4.0% from GBP604.6 million on March 31.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.